Pharmaceutical Executive August 2015

August 2015 | Volume 35, Issue 8
Pharmaceutical Executive August 2015
From the Editor
The big data revolution offers great promise for drug development versus the traditional ways of bringing medicines to market, but there is a larger issue at stake: how to turn data quantity into data quality. William Looney reports.
Commercial success for pharma brands now demands proactive strategies and interventions, writes Stacie Heller and Peter Weissberg.
New trial results spark usual range of perspectives, doubts. Casey McDonald reports.
The case of Amgen v. Sandoz signals that preliminary injunctions will play a major role in future patent disputes, write Mindy Ehrenfried and William Raich.
Despite overwhelming House approval last month of the 21st Century Cures Act, bipartisan support may fall apart in the coming months, writes Jill Wechsler.
The volatility of the nation's crisis could pose greater challenges down the line.
Adherence is no longer. The emphasis is now on patient activation, but how significant will this change be? Casey McDonald highlights how mobile tech and data ownership will certainly play a key role.
Biopharma needs to combine a “culture of quality” with value-added process improvements in manufacturing. Read on for key steps and strategies that can make a difference.
An expert panel probes the changing role of the pharmacoepidemiology function as it grapples with a raft of current challenges.
Special Sponsored Section
By Pharmaceutical Executive Editors
Despite rising healthcare costs, Algeria, the second-largest pharmaceutical market in Africa, remains optimistic about its pharma sector, which is riding the momentum of recent healthcare reforms. Manufacturing challenges and a growing prevalence of chronic disease, however, offer pause to the bright scenario.
lorem ipsum